Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery

International Journal of Pharmaceutics

Volumn 269, Issue 1, 2004, Pages 241-249

  Stoner, Chad L ^a   Cleton, Adriaan ^a,b   Johnson, Kjell ^a   Oh, Doo Man ^a,c   Hallak, Hussein ^a,d   Brodfuehrer, Joanne ^a   Surendran, Narayanan ^a   Han, Hyo Kyung ^a  

^a PFIZER INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c SANOFI   (France)

^d AL QUDS UNIVERSITY   (Palestine)

Author keywords

Bioavailability; Drug discovery; IDEA model; In vitro prediction

Indexed keywords

ACIDITY; ALKALINITY; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; MATHEMATICAL COMPUTING; METHODOLOGY; NONHUMAN; PH MEASUREMENT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLUBILITY;

EID: 0346787821     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2003.09.006     Document Type: Article

References (26)

1. Altman, P.L., Dittmer, D.S., 1972. In: Altman, P.L., Dittmer, D.S. (Eds.), Biology Data Book, vol. III. Federation of American Societies for Experimental Biology, Bethesda, p. 1704.
2. Bohets H., Annaert P., Mannens G., Beijsterveldt L.V., Anciaux K., Verboven P., Meuldermans W., Lavrijsen K. Strategies for absorption screening in drug discovery and development. Curr. Top. Med. Chem. 1:2001;367-383.
3. Chiou W.L., Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res. 15:1998;1792-1795.
4. Chiou W.L., Jeong H.Y., Chung S.M., Wu T.C. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm. Res. 17:2000;135-140.
5. Eddershaw P.J., Beresford A.P., Bayliss M.K. ADME/PK as part of a rational approach to drug discovery. Drug Discov. Today. 5:2000;409-414.
6. Hellriegel E.T., Bjornsson T.D., Hauck W.W. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin. Pharmacol. Ther. 60:1996;601-607.
7. Hodgson J. ADMET-turning chemicals into drugs. Nat. Biotech. 19:2001;722-726.
8. Horter D., Dressman J.B. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 25:1997;3-14.
9. Kibbey C.E., Poole A.K., Robinson B., Jackson J.D., Durham D. An integrated process for measuring the physicochemical properties of drug candidates in a preclinical discovery environment. J. Pharm. Sci. 90:2001;1164-1175.
10. Kramer S.F., Flynn G.L. Solubility of organic hydrochlorides. J. Pharm. Sci. 61:1972;1896-1904.
11. Lave T.H., Dupin S., Schmitt C., Valles B., Ubeaud G., Chou R.C., Jaeck D., Coassolo P.H. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm. Res. 14:1997;152-155.
12. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44:2000;235-249.
13. Naritomi Y., Terashita S., Kimura S., Suzuki A., Kagayama A., Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. 29:2001;1316-1324.
14. Obach R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 27:1999;1350-1359.
15. Obach R.S., Baxter J.G., Liston T.E., Silber B.M., Jones B.C., McIntyre F., Rance D.J., Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmcol. Exp. Ther. 283:1997;46-58.
16. Parrot N., Lavé T. Prediction of intestinal absorption: comparative assessment of GASTROPLUS™ and IDEA™ Eur. J. Pharm. Sci. 17:2002;51-61.
17. Poulin P., Theil F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91:2002;129-156.
18. Prentis R.A., Lis Y., Walker S.R. Pharmaceutical innovation by the seven U.K.-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 25:1998;387-396.
19. Rowland, M., Tozer, T.N., 1995. Clinical Pharamcokinetics: Concepts and Applications, 3rd ed. Williams & Wilkins, Baltimore.
20. Shibata Y., Takahashi H., Ishii Y. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab. Dispos. 28:2000;1518-1523.
21. Stilgenbauer, L., Surendran, N., Reddy, A., Michael, S., Liu, H., Freiwald, S., Bobrowski, W., Stoner, C., Stewart, B., 2000a. Validation of 24-well plate format for high throughput screening of permeability in caco-2 cells. AAPS Pharm. Sci. 2 (Abstract 846).
22. Stilgenbauer L., Wang Y., Surendran N., Reddy A., Michael S., Hoffman K., Tripathy S., Liu H., Freiwald S., Heimbach T., Stewart B. Automation and validation of 24-well plate format for high through put screening of metabolic stability in microsomes. AAPS Pharm. Sci. 2:2000b;147. (Abstract).
23. Theil F.-P., Guentert T.W., Haddad S., Poulin P. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol. Lett. 138:2003;29-49.
24. Venkatesh A., Lipper R.A. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89:2000;145-154.
25. Waterbeemd, H., 2001. Quantitative structure-absorption relationships. In: Testa, B. (Ed.), Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Strategies. Wiley-VCH, New York, pp. 499-511.
26. Waterbeemd H., Smith D.A., Beaumont K., Walker D.K. Property-based design: optimisation of drug absorption and pharmacokinetics. J. Med. Chem. 44:2001;1313-1333.